Pre-emptive therapy with the selective serotonin reuptake inhibitor escitalopram in patients initiating interferon therapy for hepatitis C virus (HCV) without psychiatric risk factors reduced the risk of depression, according to a recent study published in the Annals of Internal Medicine.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Escitalopram reduces the risk of depression in patients with HCV treated with interferon alpha

Newsletter